BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8978589)

  • 1. Carboplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Yamashita F; Tanaka M; Andou E; Yutani S; Kato O; Tanikawa K
    Oncology; 1997; 54(1):28-33. PubMed ID: 8978589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors.
    Lu W; Li Y; He X; Chen Y
    Hepatogastroenterology; 2003; 50(54):2079-83. PubMed ID: 14696468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
    Imai Y; Chikayama T; Nakazawa M; Watanabe K; Ando S; Mizuno Y; Yoshino K; Sugawara K; Hamaoka K; Fujimori K; Inao M; Nakayama N; Oka M; Nagoshi S; Mochida S
    J Gastroenterol; 2012 Feb; 47(2):179-86. PubMed ID: 21976133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
    Li JH; Xie XY; Zhang L; Le F; Ge NL; Li LX; Gan YH; Chen Y; Zhang JB; Xue TC; Chen RX; Xia JL; Zhang BH; Ye SL; Wang YH; Ren ZG
    World J Gastroenterol; 2015 Apr; 21(13):3970-7. PubMed ID: 25852283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma.
    Nishikawa H; Osaki Y; Kita R; Kimura T; Ohara Y; Takeda H; Sakamoto A; Saito S; Nishijima N; Nasu A; Komekado H; Nishiguchi S
    Oncol Rep; 2014 Jan; 31(1):65-72. PubMed ID: 24220763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
    Seki A; Hori S
    Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
    Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
    Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
    Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
    Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma.
    Lu W; Li YH; Yu ZJ; He XF; Chen Y; Zhao JB; Zhu ZY
    Hepatogastroenterology; 2007; 54(77):1499-502. PubMed ID: 17708284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and Management of Acute Kidney Injury in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization.
    Hong CX; Lv LW; Hua LZ; Bo S; Sen CX; Xin NY; Wei YJ; Rui XJ; Qiang DX; Zhou ZJ
    Curr Protein Pept Sci; 2017; 18(12):1218-1223. PubMed ID: 27634445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
    Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
    Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial.
    Okusaka T; Kasugai H; Shioyama Y; Tanaka K; Kudo M; Saisho H; Osaki Y; Sata M; Fujiyama S; Kumada T; Sato K; Yamamoto S; Hinotsu S; Sato T
    J Hepatol; 2009 Dec; 51(6):1030-6. PubMed ID: 19864035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcatheter arterial chemoembolization through collateral arteries for hepatocellular carcinoma after arterial occlusion.
    Shibata T; Kojima N; Tabuchi T; Itoh K; Konishi J
    Radiat Med; 1998; 16(4):251-6. PubMed ID: 9814419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
    Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K
    J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis.
    Kim JH; Yoon HK; Kim SY; Kim KM; Ko GY; Gwon DI; Sung KB
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1291-8. PubMed ID: 19392861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.